热门资讯> 正文
Aurinia Pharmaceuticals任命Kevin Tang为首席执行官
2026-03-23 20:22
- Aurinia Pharmaceuticals (AUPH) announced on Monday that Kevin Tang, Aurinia’s Chair of the Board, will succeed Peter Greenleaf as chief executive officer.
- The firm added that Greenleaf will continue as a consultant to facilitate the transition.
- The company has also appointed Ryan Cole as chief operating officer, Michael Hearne as chief financial officer, and Thomas Wei as chief scientific officer.
- Additionally, Stew Kroll and Stephen Robertson will continue in their roles as chief development officer and general counsel, respectively.
- AUPH +0.85% premarket to $14.14.
- Source: Press Release
More on Aurinia Pharma
- Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade)
- Aurinia targets $305M–$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development
- Seeking Alpha’s Quant Rating on Aurinia Pharma
- Historical earnings data for Aurinia Pharma
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。